摘要
近年来,恶性肿瘤已成为一种发病率较高的慢性病,尤其是结直肠癌的发病率和死亡率呈逐渐上升趋势。目前伊立替康联合5-氟尿嘧啶与亚叶酸钙方案(FOLFIRI)治疗晚期结直肠癌疗效显著。但由于伊立替康严重的不良反应及明显的个体差异,该方案在临床应用中受到一定限制。伊立替康在体内代谢过程中受多种酶的影响,其中尿苷二磷酸葡糖醛酸转移酶1Al(UGT1A1)在伊立替康体内代谢过程中起到核心作用。但随着深入研究,伊立替康及其代谢物的血药浓度在预测伊立替康相关不良反应甚至个体化给药方面与基因多态性检测同样重要。因此,本文就影响伊立替康个体化治疗的因素作一综述。
Malignant tumor has become a chronic disease with a high incidence, especially the colorectal cancer whose incidence and mortality increased. Irinotecan combined 5-fluorouracil and leucovorin calcium solution（FOLFIRI） is the classic regimen of colorectal cancer, but is limited in the clinical application due to its adverse effects and obvious individual difference. Recent reports showed genetic polymorphisms of UDP glucuronyl transferase-1 polypeptide A1（UGT1A1）, a glucuronidation enzyme, were associated with irinotecan metabolism. Several studies suggested that the plasma concentration of irinotecan and its metabolism were associated with potentially serious adverse effects and even dose adjustments, which are equally important as gene polymorphism. This paper reviews the factors that affect the individualized treatment with irinotecan.
出处
《中南药学》
CAS
2015年第11期1178-1182,共5页
Central South Pharmacy
关键词
伊立替康
UGT1A1
血药浓度
个体化治疗
irinotecan
UDP glucuronyl transferase-1 polypeptide A1 polymorphism
plasma concentration
individu-alized treatment
